GE HealthCare (GEHC) · Medical Devices
GE HealthCare Q2 2026 earnings: summary, key numbers & outlook
Results filed 29 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
GE HealthCare's combined imaging segment and growing theranostics push drove orders across every segment, while Patient Care Solutions struggled and is now under strategic review.
GE HealthCare merged its Imaging and Advanced Visualization Solutions businesses into one segment, Advanced Imaging Solutions, leaving three reportable segments. Orders grew in every segment, which management tied to commercial execution and adoption of new products, with backlog at $23.9 billion. Pharmaceutical Diagnostics and Advanced Imaging Solutions led growth. Partnerships in theranostics (with Mayo Clinic and University Hospital Essen) and a health system deal on Long Island expanded the footprint. Patient Care Solutions kept shrinking.
Management is steering toward precision innovation, meaning AI-enabled imaging, nuclear medicine, theranostics and cloud software, while reviewing strategic options for Patient Care Solutions. The main tension is that the company is investing for growth while a weak segment drags on performance and costs rise for memory chips, oil and freight, roughly $250 million of inflation expected this year. Tariff refunds are not a lasting benefit.
No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.
Key numbers
- Revenue · GAAP
- $5.3 billion
- Net income attributable to GE HealthCare · GAAP
- $561 million
- Diluted EPS · GAAP
- $1.24
- Adjusted EPS · non-GAAP
- $1.13
- Adjusted EBIT margin · non-GAAP
- 14.2%
- Cash flow from operating activities · GAAP
- $168 million
- Free cash flow · non-GAAP
- $68 million
- Organic orders growth · non-GAAP
- 11.1%
up 5.7% from a year ago
versus $486 million a year ago
grew 16.5%
grew 6.6%
versus 14.6%, down 40 bps
up $74 million
up $61 million
versus 3.4% growth in the year-ago period
| Segment or metric | Value | Change |
|---|---|---|
| Advanced Imaging Solutions revenue | $3.8B | up 7.9%; organic up 5.0% |
| Pharmaceutical Diagnostics revenue | $843.0M | up 15.6%; organic up 14.6% |
| Patient Care Solutions revenue | $675.0M | down 13.3%; organic down 13.5% |
| Backlog | $23.9 billion | book-to-bill of 1.15 times |
Where each number comes from
- Revenue: “Revenues of $5.3 billion, up 5.7%, including Organic revenue growth* of 3.5%, driven by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS)”
- Net income attributable to GE HealthCare: “Net income attributable to GE HealthCare of $561 million versus $486 million, and Adjusted EBIT* of $750 million versus $729 million”
- Diluted EPS: “diluted earnings per share (EPS) of $1.24 grew 16.5% and Adjusted EPS* of $1.13 grew 6.6%”
- Adjusted EPS: “diluted earnings per share (EPS) of $1.24 grew 16.5% and Adjusted EPS* of $1.13 grew 6.6%”
- Adjusted EBIT margin: “Adjusted EBIT margin* of 14.2% versus 14.6%, down 40 bps, with both measures negatively impacted by a decline in PCS”
- Cash flow from operating activities: “Cash flow from operating activities of $168 million, up $74 million. Free cash flow* of $68 million, up $61 million.”
- Free cash flow: “Cash flow from operating activities of $168 million, up $74 million. Free cash flow* of $68 million, up $61 million.”
- Organic orders growth: “Total orders up 11.1% organically versus 3.4% growth in the year-ago period, book-to-bill of 1.15 times and backlog of $23.9 billion.”
- Advanced Imaging Solutions revenue: “Segment($ in millions) | Advanced Imaging Solutions | Pharmaceutical Diagnostics | Patient Care Solutions Segment Revenues | $3,771 | $843 | $675”
- Pharmaceutical Diagnostics revenue: “Segment($ in millions) | Advanced Imaging Solutions | Pharmaceutical Diagnostics | Patient Care Solutions Segment Revenues | $3,771 | $843 | $675”
- Patient Care Solutions revenue: “Segment($ in millions) | Advanced Imaging Solutions | Pharmaceutical Diagnostics | Patient Care Solutions Segment Revenues | $3,771 | $843 | $675”
- Backlog: “Total orders up 11.1% organically versus 3.4% growth in the year-ago period, book-to-bill of 1.15 times and backlog of $23.9 billion.”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $5.3B | +5.8% | +3.2% |
| Operating income | $739.0M | +13.0% | +43.5% |
| Net income | $561.0M | +15.4% | +44.2% |
| Diluted EPS | $1.24 | +17.0% | +45.9% |
| Free cash flow | $68.0M | +750.0% | −39.3% |
| Gross margin | 41.2% | +1.6 pts | +2.7 pts |
| Operating margin | 14.0% | +0.9 pts | +4.0 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Organic revenue growth | full-year 2026 | 3.0% to 4.0% |
| Adjusted EBIT margin | full-year 2026 | 15.4% to 15.7% |
| Adjusted effective tax rate | full-year 2026 | 20.0% to 21.0% |
| Adjusted EPS | full-year 2026 | $4.80 to $5.00 |
| Free cash flow | full-year 2026 | approximately $1.6 billion |
| Inflation from memory chips, oil, freight and other components | full-year 2026 | approximately $250 million |
Key takeaways
Orders grew in every segment, with record backlog
Total orders rose 11.1% organically with book-to-bill of 1.15 times, leaving backlog at $23.9 billion. Management credited commercial execution and adoption of new products, which signals demand ahead of revenue.
Patient Care Solutions is under strategic review
The segment's organic revenue fell 13.5% and it posted a loss at the segment level. The CEO said the company is focused on returning it to growth and profitability while reviewing strategic options to maximize its long-term value.
Two imaging businesses combined into Advanced Imaging Solutions
Imaging and Advanced Visualization Solutions now report as one segment, leaving three reportable segments. The new segment produced the largest share of revenue, with 5.0% organic growth.
Theranostics partnerships widen the personalized cancer care push
GE HealthCare announced a research collaboration with Mayo Clinic and a new Nuclear Medicine Center with University Hospital Essen. These extend the Pharmaceutical Diagnostics and nuclear medicine strategy, with PDx organic revenue up 14.6%.
AI and cloud software keep expanding the portfolio
The company received FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0 for radiation therapy planning and submitted MIM KineticID for 4D dynamic PET imaging. It also promoted cloud-enabled enterprise imaging, reflecting the stated focus on cloud, edge computing and AI.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $5.3B * |
| Q1 2025 | $4.8B |
| Q2 2025 | $5.0B |
| Q3 2025 | $5.1B |
| Q4 2025 | $5.7B * |
| Q1 2026 | $5.1B |
| Q2 2026 | $5.3B |
| Q3 2026 | $5.5B |
Data
| Q1 2025 | $1.23 |
| Q2 2025 | $1.06 |
| Q3 2025 | $0.98 |
| Q1 2026 | $0.85 |
| Q2 2026 | $1.24 |
| Q3 2026 | $1.36 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 15.1% |
| Q1 2025 | 13.2% |
| Q2 2025 | 13.1% |
| Q3 2025 | 12.7% |
| Q4 2025 | 14.5% |
| Q1 2026 | 10.0% |
| Q2 2026 | 14.0% |
| Q3 2026 | 14.6% |
Data
| Q1 2025 | $98.0M |
| Q2 2025 | $8.0M |
| Q3 2025 | $483.0M |
| Q1 2026 | $112.0M |
| Q2 2026 | $68.0M |
| Q3 2026 | $793.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What changed in GE HealthCare's reporting structure this quarter?
It combined Imaging and Advanced Visualization Solutions into a new segment, Advanced Imaging Solutions. The company now reports three segments: Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions, with history recast.
What is GE HealthCare doing about Patient Care Solutions?
The CEO said management is focused on returning the business to growth and profitability while reviewing strategic options to maximize its long-term value. The segment's organic revenue declined 13.5% this quarter.
How strong was customer demand in the quarter?
Organic orders grew 11.1%, versus 3.4% a year earlier, with growth in every segment. Book-to-bill was 1.15 times and backlog reached $23.9 billion.
Where is GE HealthCare investing in new products and partnerships?
It is investing in theranostics and nuclear medicine through collaborations with Mayo Clinic and University Hospital Essen, and in AI tools such as MIM Contour ProtégéAI+ 2.0 and MIM KineticID. It also highlighted cloud-enabled enterprise imaging and a partnership with Catholic Health on Long Island.
What cost pressures is management flagging?
Management continues to expect approximately $250 million of inflation tied to memory chips, oil, freight and other components this year. The company also said it does not expect a material further benefit from tariff refunds for 2026 tariffs, and it reaffirmed its full-year guidance.
Documents
SEC filing